Elicitation of α4β7-Competitive Antibodies in Rhesus Macaques by a Synthetic V2 Immunogen

合成 V2 免疫原在恒河猴中诱导 α4β7 竞争性抗体

• 批准号: 9559805
• 负责人: Ronald S. Veazey
• 金额: $ 30.34万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-01 至 2018-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9559805
• 关键词: AIDS Vaccines; AIDS vaccine development; Advanced Development; Antibodies; Antigens; Award; Clinical; Complement; Contracts; Development; Evaluation Studies; Funding; Grant; HIV vaccine; Immune; Investigator-Initiated Research; Local Microbicides; Macaca mulatta; Modality; National Institute of Allergy and Infectious Disease; Prevention; Prevention strategy; Research Personnel; Research Project Grants; Resources; Vaccine Design; Vaccine Research; Vaccines; base; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; programs; vaccine candidate; vaccine evaluation

The development of HIV vaccines and other prevention strategies relies on the use of nonhuman primates in preclinical studies to advance the development of effective AIDS vaccine candidates and to advance development of effective topical microbicides and other prevention modalities or immune-based therapies. The NIAID Simian Vaccine Evaluation Unit (SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators. These studies complement NIAID-supported basic vaccine research and vaccine evaluation studies funded through R01 (investigator-initiated research) grants, HIVRAD (HIV Vaccine Research and Design Program) grants, IPCAVD (Integrated Preclinical-Clinical AIDS Vaccine Development) grants, and NHP Consortium awards. The SVEUs also perform studies of candidate vaccines offered by companies or other researchers. The primary activity is to conduct a study to elicit α4β7- competitive antibodies in non-human primates.

HIV 疫苗和其他预防策略的开发依赖于在临床前研究中使用非人类灵长类动物来推动有效的艾滋病候选疫苗的开发，并推动有效的局部杀菌剂和其他预防方式或基于免疫的疗法的开发。评估单位（SVEU）合同应提供主要支持艾滋病疫苗临床前评估的非人类灵长类资源。SVEU 开展研究以支持广泛的研究人员正在开发的疫苗。 NIAID 支持的基础疫苗研究和疫苗评估研究通过 R01（研究者发起的研究）拨款、HIVRAD（艾滋病毒疫苗研究和设计计划）拨款、IPCAVD（临床前-临床综合艾滋病疫苗开发）拨款和 NHP 联盟奖项资助。还对公司或其他研究人员提供的候选疫苗进行研究，主要活动是在非人类体内引发 α4β7 竞争性抗体。灵长类动物。